相关临床试验
215
215 进行中
药物批准
53
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
215
100.0%
- Two U.S. biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, have launched early-stage clinical trials testing GLP-1 weight-loss therapies for overweight and obese cats. - Approximately 61% of cats and 59% of dogs evaluated by U.S. veterinary professionals in 2022 were classified as overweight or obese, according to the Association for Pet Obesity Prevention. - Morgan Stanley analyst Simeon Gutman describes the trend as "an expansion from premiumization into medicalization," with U.S. pet spending projected to grow from $196 billion in 2025 to over $240 billion by 2030. - Top-line results from both feline GLP-1 clinical trials are expected later this year, though affordability concerns may constrain widespread adoption in veterinary medicine.
- Zoetis has received regulatory approval for Lenivia, a new monoclonal antibody therapy for canine osteoarthritis, expanding its Companion Animal portfolio. - The approval offers veterinarians an additional osteoarthritis treatment option alongside the company's existing Librela product. - The launch comes amid ongoing securities class actions alleging misleading statements about Companion Animal growth and safety concerns related to Librela. - Investors are watching closely for adoption rates in the UK market and how Zoetis positions Lenivia relative to its other pain therapies.
